Mineralys Therapeutics, Inc.
MLYS
$27.38
$0.110.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -151.78M | -154.65M | -171.36M | -190.77M | -188.51M |
| Total Depreciation and Amortization | 50.00K | 59.00K | 61.00K | 57.00K | 50.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.77M | 9.45M | 10.17M | 7.15M | 4.85M |
| Change in Net Operating Assets | 6.56M | 2.73M | -10.23M | -9.12M | -9.05M |
| Cash from Operations | -136.40M | -142.42M | -171.37M | -192.69M | -192.66M |
| Capital Expenditure | -15.00K | -15.00K | 0.00 | -37.00K | -37.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -341.81M | -389.74M | -202.69M | 27.46M | 78.07M |
| Cash from Investing | -341.82M | -389.75M | -202.69M | 27.42M | 78.04M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 426.37M | 591.39M | 494.52M | 199.34M | 189.60M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -382.00K | -391.00K | -133.00K | -145.00K | -382.00K |
| Cash from Financing | 425.99M | 591.00M | 494.39M | 199.20M | 189.22M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.23M | 58.83M | 120.32M | 33.93M | 74.59M |